| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H26N6O |
| Molecular Weight | 426.5135 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NN=NN5)C(=O)CCCC2
InChI
InChIKey=KCTFTBCZZUBAKN-UHFFFAOYSA-N
InChI=1S/C25H26N6O/c1-2-7-23-26-21-10-5-6-11-22(32)24(21)31(23)16-17-12-14-18(15-13-17)19-8-3-4-9-20(19)25-27-29-30-28-25/h3-4,8-9,12-15H,2,5-7,10-11,16H2,1H3,(H,27,28,29,30)
| Molecular Formula | C25H26N6O |
| Molecular Weight | 426.5135 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pratosartan is an orally active angiotensin II type 1 receptor blocker. It is being developed for the treatment of hypertension. Pratosartan was efficacious throughout the long-term study, without serious adverse effects. Pratosartan significantly decreased serum total cholesterol in patients with hypercholesterolemia and uric acid in patients with hyperuricemia. It may have beneficial effects on hypertensive patients with some metabolic disorders. Pratosartan is still in phase III development in South Korea and phase II in Japan for hypertension.
